Preview

Опухоли головы и шеи

Расширенный поиск

ДИАГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ ИССЛЕДОВАНИЯ РОТОВОЙ ЖИДКОСТИ В ОНКОЛОГИИ

https://doi.org/10.17650/2222-1468-2013-0-1-39-42

Полный текст:

Аннотация

Заболеваемость населения России злокачественными новообразованиями (ЗН) челюстно-лицевой области увеличивается каждый год на 1,53 %. Прирост за период с 2000 по 2010 г. составляет 16,39 %. Высокий уровень заболеваемости актуализирует проблему ранней диагностики. В этом плане определение биомаркеров в слюне является новым подходом к проблеме диагностики ЗН полости рта, стадий развития, включая начальный процесс, распространение, рецидив и лечение.

Об авторах

В. Н. Николенко
ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России
Россия


С. В. Козлов
ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России
Россия


Е. В. Кочурова
ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России
Россия


Список литературы

1. Petersen P.E. Strengthening the prevention of oral cancer: the WHO perspective. Community Dent Oral Epidemiol 2005;33(6):397–9.

2. Чиссов В.И., Старинский В.В., Петров а Г.В. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрав- соцразвития России, 2012.

3. American Cancer Society: Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society, 2012.

4. Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, Version 1.0. Lyon: IARC Press, 2001.

5. Peacock Z.S., Pogrel M.A., Schmidt B.L. Exploring the reasons for delay in treatment of oral cancer. J Am Dent Assoc 2008;139(10):1346–52.

6. Schantz S.P. Biologic markers, cellular differentiation, and metastatic head and neck cancer. Eur Arch Otorhinolaryngol 1993;250(8):424–8.

7. Schantz S.P. Carcinogenesis, markers, staging, and prognosis of head and neck cancer. Curr Opin Oncol 1993;5(3):483–90.

8. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2(3):210–9.

9. Ellison M.D., Campbell B.H. Screening for cancers of the head and neck: addressing the problem. Surg Oncol Clin N Am 1999;8(4):725–34.

10. Azuma M., Kasai Y., Tamatani T., Sato M. Involvement of p53 mutation in the development of human salivary gland pleomorphic adenomas. Cancer Lett 1992;65(1):61–71.

11. Streckfus C., Bigler L., Tucci M., Thigpen J.T. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma. Cancer Invest 2000;18(2):101–9.

12. Corstjens PLAMMD. Point-of-care Diagnostics for infectious diseases. In: Wong D.T., editor. Saliva Diagnostics. Ames: Wiley-Blackwell, 2008. Pp. 243–254.

13. Farnaud S.J., Kosti O., Getting S.J., Renshaw D. Saliva: physiology and diagnostic potential in health and disease. Scientific World Journal 2010;10:434–56.

14. Streckfus C., Bigler L. The use of soluble, salivary c-erbB-2 for the detection and post-operative follow-up of breast cancer in women: the results of a five-year translational research study. Adv Dent Res 2005;18(1):17–24.

15. Chen D.X., Schwartz P.E., Li F.Q. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol 1990;75(4):701–4.

16. Blackburn A.C., Hill L.Z., Roberts A.L. et al. Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk. Am J Pathol 2007;170(6):2030–41.

17. Braidotti P., Nuciforo P.G., Mollenhauer J. et al. DMBT1 expression is down-regulated in breast cancer. BMC Cancer 2004;4:46.

18. Zhаng L., Hуnsоn B.S., Cаmаrgо Р.М., Wong D.T. The clinical value of salivary biomarkers for periodontal disease. Periodontol 2000. 2009;51:25–37.

19. Malamud D. Saliva as a diagnostic fluid. Dent Clin North Am 2011;55(1):159–78.

20. Schmidt B., Engel E., Carstensen T. et al. Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection? Lung Cancer 2005;48(1):145–7.

21. Kopreski M.S., Benko F.A., Gocke C.D. Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum. Ann N Y Acad Sci 2001;945:172–8.

22. Hasselmann D.O., Rappl G., Rössler M. et al. Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Rep 2001;8(1):115–8.

23. Bryzgunova O.E., Skvortsova T.E., Kolesnikova E.V. et al. Isolation and comparative study of cell-free nucleic acids from human urine. Ann N Y Acad Sci 2006;1075:334–40.

24. Yoneda K., Iida H., Endo H. et al. Identification of Cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol 2009;35(1):33–40.

25. St. John M., Li Y., Zhou X. et al. Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130(8):929–35.

26. Li Y., St. John M.A., Zhou X. et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004;10(24):8442–50.

27. De Bont J.M., van Doorn J., Reddingius R.E. et al. Various components of the insulin-like growth factor system in tumour tissue, cerebrospinal fluid and peripheral blood of pediatric medulloblastoma and ependymoma patients. Int J Cancer 2008;123(3):594–600.

28. Johnson P.J., Lo Y.M. Plasma nucleic acids in the diagnosis and management of malignant disease. Clin Chem 2002;48(8):1186–93.

29. Neves A.F., Araújo T.G., Biase W.K. et al. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 2008;41(14–15): 1191–8.

30. Honma H., Kanda T., Ito H. et al. Squamous cell carcinoma-antigen messenger RNA level in peripheral blood predicts recurrence after resection in patients with esophageal squamous cell carcinoma. Surgery 2006;139(5):678–85.

31. El-Abd E., El-Tahan R., Fahmy L. et al. Serum metastasin mRNA is an important survival predictor in breast cancer. Br J Biomed Sci 2008;65(2):90–4.

32. Voorzanger-Rousselot N., Goehrig D., Journe F. et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007;97(7):964–70.

33. Siddiqua A., Chendil D., Rowland R. et al. Increased expression of PSA mRNA during brachytherapy in peripheral blood of patients with prostate cancer. Urology 2002;60(2):270–5.

34. Ogawa O., Iinuma M., Sato K. et al. Circulating prostate-specific antigen mRNA during radical prostatectomy in patients with localized prostate cancer: with special reference to neoadjuvant hormonal therapy. Urol Res 1999;27(4):291–6.

35. Zheng M., Li L., Tang Y.L. et al. Biomarkers in tongue cancer: understanding the molecular basis and their clinical implications. Postgrad Med J 2010;86(1015):292–8.

36. Petersen P.E. Oral cancer prevention and control – the approach of the World Health Organization. Oral Oncol 2009;45(4–5): 454–60.

37. Meurman J.H. Infectious and dietary risk factors of oral cancer. Oral Oncol 2010;46(6):411–3.

38. Fedele S. Diagnostic aids in the screening of oral cancer. Head Neck Oncol 2009 Jan 30;1:5.

39. Zakzerwska J.M., Hindle I., Speight P.M. Practical considerations for the establishment of an oral cancer screening programme. Commun Dent Health 1993;10(1):79–85.

40. Christian D.C. Computer-assisted analysis of oral brush biopsies at an oral cancer screening program. J Am Dent Assoc 2002;133(3):357–62.

41. Mehrotra R., Hullmann M., Smeets R. et al. Oral cytology revisited. J Oral Pathol Med 2009;38(2):161–6.

42. Güneri P., Epstein J.B., Ergün S., Boyacioğlu H. Toluidine blue color perception in identification of oral mucosal lesions. Clin Oral Investig 2011;15(3):337–45.

43. Onofre M.A., Sposto M.R., Navarro C.M. Reliability of toluidine application in the detection of oral epithelial dysplasia and in situ and invasive squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(5):535–40.

44. Zhang L., Williams M., Poh C.F. et al. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. Cancer Res 2005;65(17):8017–21.

45. Seoane Leston J., Diz Dios P. Diagnostic clinical aids in oral cancer. Oral Oncol 2010;46(6):418–22.

46. Kerr A.R., Sirois D.A., Epstein J.B. Clinical evaluation of chemiluminescent lighting: an adjunct for oral mucosal examinations. J Clin Dent 2006;17(3):59–63.

47. Epstein J.B., Silverman S. Jr, Epstein J.D. et al. Analysis of oral lesion biopsies identified and evaluated by visual examination, chemiluminescence and tolouidine blue. Oral Oncol 2008;44(6):538–44.

48. Onizawa K., Saginoya H., Furuya Y., Yoshida H. Fluorescence photography as a diagnostic method for oral cancer. Cancer Lett 1996(1);108:61–6.

49. Floriano P.N., Christodoulides N., Miller C.S. et al. Use of saliva-based nanobiochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem 2009;55(8):1530–8.

50. Zimmermann B.G., Park N.J., Wong D.T. Genomic targets in saliva. Ann N Y Acad Sci 2007;1098:184–91.

51. Xie H., Onsongo G., Popko J. et al. Proteomics analysis of cells in whole saliva from oral cancer patients via value-added three-dimensional peptide fractionation and tandem mass spectrometry. Mol Cell Proteomics 2008;7(3):486–98.

52. Williams M.D. Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol 2010;4(1):62–9.

53. Sugimoto M., Wong D.T., Hirayama A. et al. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancerspecific profiles. Metabolomics 2010;6(1):78–95.

54. Lee J.M., Garon E., Wong D.T. Salivary diagnostics. Orthod Craniofac Res 2009;12(3):206–11.

55. Hu S., Arellano M., Boontheung P. et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 2008;14(19):6246–52.

56. Bigler L.R., Streckfus C.F., Dubinsky W.P. Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med 2009;29(1):71–85.

57. Bilodeau E., Alawi F., Costello B.J., Prasad J.L. Molecular diagnostics for head and neck pathology. Oral Maxillofac Surg Clin North Am 2010;22(1):183–94.

58. Ramseier C.A., Kinney J.S., Herr A.E. et al. Identification of pathogen and hostresponse markers correlated with periodontal disease. J Periodontol 2009;80(3):436–46.

59. Herr A.E., Hatch A.V., Giannobile W.V. et al. Integrated microfluidic platform for oral diagnostics. Ann N Y Acad Sci 2007;1098:362–74.

60. Kakoei S., Haghdoost А.А., Rad M. et al. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Arch Iran Med 2012;15(4):214–8.


Для цитирования:


Николенко В.Н., Козлов С.В., Кочурова Е.В. ДИАГНОСТИЧЕСКАЯ ЗНАЧИМОСТЬ ИССЛЕДОВАНИЯ РОТОВОЙ ЖИДКОСТИ В ОНКОЛОГИИ. Опухоли головы и шеи. 2013;(1):39-42. https://doi.org/10.17650/2222-1468-2013-0-1-39-42

For citation:


Nikolenko V.N., Kozlov S.V., Kochurova E.V. DIAGNOSTIC ABILITIES OF THE ORAL FLUID IN ONCOLOGY. Head and Neck Tumors (HNT). 2013;(1):39-42. (In Russ.) https://doi.org/10.17650/2222-1468-2013-0-1-39-42

Просмотров: 290


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2222-1468 (Print)
ISSN 2411-4634 (Online)